Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar 14:13:850759.
doi: 10.3389/fimmu.2022.850759. eCollection 2022.

Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters

Jamil A Al-Mughales  1   2
Affiliations

Anti-Nuclear Antibodies Patterns in Patients With Systemic Lupus Erythematosus and Their Correlation With Other Diagnostic Immunological Parameters

Jamil A Al-Mughales. Front Immunol. .

Abstract

Background: Antinuclear antibodies (ANA) are major immunodiagnostic tools in systemic lupus erythematosus (SLE); however, their clinical and pathogenic roles are not yet elucidated and are a subject of controversy.

Objectives: The aim of the study is to explore the pathogenic significance of ANA patterns among SLE patients, by analyzing their association with ANA titers, complement levels and other pathogenic immune markers, namely, anti-double-stranded DNA (anti-dsDNA), complements C3 and C4, rheumatoid factor (RF), anticardiolipin antibodies IgG (ACL IgG) and IgM (ACL IgM), Beta-2 Glycoprotein 1 Antibodies (β2-GP) IgG (β2-IgM) and IgM (β2-IgM), and lupus anticoagulant (LA).

Method: A comparative cross-sectional study was conducted among 495 SLE patients, who were diagnosed and classified by consultant rheumatologists according to the new European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 criteria. SLE immunodiagnostic profiles were analyzed including the following parameters: ANA antibody titers and staining patterns, anti-dsDNA, C3 and C4 levels, aCL, and anti-β2-GP and LA.

Result: The most frequently observed ANA patterns were the speckled (52.1%) and homogeneous (35.2%) patterns, while other patterns were rare representing less than 7% of the patients each. ANA titers were highest in patients with mixed pattern followed by the speckled pattern. Of all the investigated patterns, the peripheral pattern showed the most pathogenic immune profile, namely, highest levels of anti-dsDNA, lowest levels of C4, and highest levels of aCL and β2-GP IgG and IgM.

Conclusion: This retrospective study showed that speckled followed by homogeneous ANA patterns were predominant accounting for 52.1 and 35.2% of the patients. The ANA pattern showed several associations with other immune markers that are documented to have significant clinical implications in SLE. Peripheral, mixed, and speckled patterns were associated with higher profiles of immune markers indicative of a potential prognostic value of these patterns in SLE.

Keywords: ANA; SlE; anti-dsDNA; antinuclear antibodies; immunofluorescence; patterns; systemic lupus erythematosus.

PubMed Disclaimer

Conflict of interest statement

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Summary of the significant associations of ANA patterns with other immune markers in patients with SLE. * Significance confirmed by post hoc analysis.
See this image and copyright information in PMC

References

    1. Györi N, Giannakou I, Chatzidionysiou K, Magder L, van Vollenhoven RF, Petri M. Disease Activity Patterns Over Time in Patients With SLE: Analysis of the Hopkins Lupus Cohort. Lupus Sci Med (2017) 4:e000192. doi: 10.1136/lupus-2016-000192 - DOI - PMC - PubMed
    1. Karnal EM, Fabian J, Carlesso LC, Gelinski JMLN. Primary Nutritional Guidance at Systemic Lupus Erythematosus. J Sci Res Rep (2020) 26:10–9. doi: 10.9734/jsrr/2020/v26i530256 - DOI
    1. Fava A, Petri M. Systemic Lupus Erythematosus: Diagnosis and Clinical Management. J Autoimmun (2019) 96:1–13. doi: 10.1016/j.jaut.2018.11.001 - DOI - PMC - PubMed
    1. Gurevitz SL, Snyder JA, Wessel EK, Frey J, Williamson BA. Systemic Lupus Erythematosus: A Review of the Disease and Treatment Options. Consult Pharm (2013) 28:110–21. doi: 10.4140/TCP.n.2013.110 - DOI - PubMed
    1. Yaniv G, Twig G, Shor DB, Furer A, Sherer Y, Mozes O, et al. . A Volcanic Explosion of Autoantibodies in Systemic Lupus Erythematosus: A Diversity of 180 Different Antibodies Found in SLE Patients. Autoimmun Rev (2015) 14:75–9. doi: 10.1016/j.autrev.2014.10.003 - DOI - PubMed

Publication types